Q32 Bio To Reveal 36-Week Topline Results From Part B Of The SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe Aa On July 13, 2026

Loading news article.

Q32 Bio To Reveal 36-Week Topline Results From Part B Of The SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe Aa On July 13, 2026 | WAPE

Q32 Bio To Reveal 36-Week Topline Results From Part B Of The SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe Aa On July 13, 2026

Article summary

Related companies

Comments —